Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Celldex Therapeutics Inc (NASDAQ: CLDX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Celldex Therapeutics Inc (NASDAQ: CLDX) concerning whether a series of statements by Celldex Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 7, 2016, Celldex Therapeutics disclosed that it's discontinuing its late-stage study of RINTEGA. Celldex Therapeutics stated that an independent Data Safety and Monitoring Board found that the trial will likely “not reach statistical significant for overall survival in patients with minimal residual disease, the primary end-point of the study.”

On this news, Celldex shares declined more than 50% on intraday trading On March 7, 2016.

Based in Hampton, New Jersey, Celldex Therapeutics Inc is a biopharmaceutical company, developing, manufacturing, and commercializing novel therapeutics for human health care.

If you purchased shares of Celldex Therapeutics Inc (NASDAQ: CLDX) on or before March 7, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185